@article{75752b32cdd641aabde01b6dd34ecfb4,
title = "Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer – Authors' reply",
author = "{KEYNOTE-057 investigators} and Balar, {Arjun V.} and Kamat, {Ashish M.} and {de Wit}, Ronald",
note = "Funding Information: AVB reports research funding from AstraZeneca/MedImmune, Genentech/Roche, Merck Sharp & Dohme, and Seattle Genetics; has been a consultant to AstraZeneca/MedImmune, Cerulean Pharma, Genentech/Roche, Incyte, Merck Sharp & Dohme, Pfizer/EMD Serono, and Seattle Genetics/Astellas; and honoraria from AstraZeneca/MedImmune, Genentech/Roche, and Merck Sharp & Dohme. AMK reports research funding from FKD Industries and Merck Sharp & Dohme; honoraria from UroToday Publishing and EAU (EU Oncology); has been a consultant to Merck Sharp & Dohme, Bristol Myers Squibb, Imagin, Eisai, Arquer, MDX Health, Photocure, AstraZeneca, Tesaro, Abbott Molecular, US Biotest, Ferring, and BioClinica; travel expenses from Pfizer Japan; holds patents for CyPRIT-Cytokine Panel for Response to Intravesical Immunotherapy; and is the president of the International Bladder Cancer Group and the International Bladder Cancer Network. RdW reports research funding from Bayer and Sanofi; has been a consultant to Astellas, Merck Sharp & Dohme, Roche/Genentech, and Sanofi; and honoraria from Astellas, Bayer, Janssen, Merck Sharp & Dohme, Roche/Genentech, and Sanofi.",
year = "2021",
month = sep,
doi = "10.1016/S1470-2045(21)00478-2",
language = "English (US)",
volume = "22",
pages = "e380",
journal = "The lancet oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "9",
}